Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 63, Issue 12, 2011, Pages 3692-3701

  Sellam, Jérémie ^a,b,l,m   Rouanet, Stéphanie ^c   Hendel Chavez, Houria ^a,b   Abbed, Karim ^a,b   Sibilia, Jean ^d,e   Tebib, Jacques ^f   Le Loët, Xavier ^g   Combe, Bernard ^h,i   Dougados, Maxime ^j,k   Mariette, Xavier ^a,b   Taoufik, Yassine ^c  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Roche ^*  (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g ROUEN UNIVERSITY HOSPITAL   (France)

^h LAPEYRONIE HOSPITAL   (France)

ⁱ INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k AP HP ^*  (France)

^l HÔPITAL SAINT ANTOINE   (France)

^m SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; B CELL ACTIVATING FACTOR RECEPTOR; CD27 ANTIGEN; ETANERCEPT; IMMUNOGLOBULIN D; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD27; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTE SUBSETS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOCYTE DEPLETION; MALE; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 82455210480     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30599     Document Type: Article

References (42)

1. Sibilia J, Gottenberg JE, Mariette X,. Rituximab: a new therapeutic alternative in rheumatoid arthritis. Joint Bone Spine 2008; 75: 526-32.
2. Sanz I, Anolik JH, Looney RJ,. B cell depletion therapy in autoimmune diseases. Front Biosci 2007; 12: 2546-67.
3. Roll P, Dorner T, Tony HP,. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566-75. (Pubitemid 351847509)
4. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP,. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2377-86. (Pubitemid 44204997)
5. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62: 1273-9.
6. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002; 46: 2160-71.
7. Hansen A, Gosemann M, Pruss A, Reiter K, Ruzickova S, Lipsky PE, et al. Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum 2004; 50: 1897-908. (Pubitemid 38725102)
8. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V,. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001; 167: 2361-9. (Pubitemid 32747551)
9. Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C, et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 790-7. (Pubitemid 46846699)
10. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-90. (Pubitemid 39488683)
11. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I,. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009. E-pub ahead of print.
12. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008; 180: 688-92.
13. Fekete A, Soos L, Szekanecz Z, Szabo Z, Szodoray P, Barath S, et al. Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. J Autoimmun 2007; 29: 154-63. (Pubitemid 47385116)
14. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009; 11: R84.
15. Mackay F, Figgett WA, Saulep D, Lepage M, Hibbs ML,. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010; 237: 205-25.
16. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-710. (Pubitemid 30002351)
17. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56. (Pubitemid 29272691)
18. Nakajima K, Itoh K, Nagatani K, Okawa-Takatsuji M, Fujii T, Kuroki H, et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007; 36: 365-72. (Pubitemid 350034808)
19. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174: 864-70. (Pubitemid 40094281)
20. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003; 62: 168-71. (Pubitemid 36135394)
21. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34-9. (Pubitemid 41129420)
22. De la Torre I, Moura RA, Leandro MJ, Edwards J, Cambridge G,. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy [published erratum appears in Ann Rheum Dis 2011;70:1350]. Ann Rheum Dis 2010; 69: 2181-8.
23. Landau DA, Rosenzwajg M, Saadoun D, Klatzmann D, Cacoub P,. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Ann Rheum Dis 2009; 68: 337-44.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
25. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
26. Van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al, for the American College of Rheumatology and the European League of Associations for Rheumatology. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999; 26: 705-11. (Pubitemid 29125596)
27. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40. (Pubitemid 26036375)
28. Klein U, Rajewsky K, Kuppers R,. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998; 188: 1679-89. (Pubitemid 28516113)
29. Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas JJ, Rodriguez C, Brieva JA,. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res Ther 2010; 12: R108.
30. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007; 178: 6624-33. (Pubitemid 46717447)
31. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008; 58: 1762-73. (Pubitemid 351847530)
32. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM,. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome. J Immunol 2001; 167: 3610-8. (Pubitemid 32916053)
33. Bohnhorst JO, Thoen JE, Natvig JB, Thompson KM,. Significantly depressed percentage of CD27+ (memory) B cells among peripheral blood B cells in patients with primary Sjögren's syndrome. Scand J Immunol 2001; 54: 421-7. (Pubitemid 32958579)
34. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loet X, et al. B cell activation biomarkers as predictive factors of response to rituximab in refractory rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011; 63: 933-8.
35. Anolik J, Sanz I, Looney RJ,. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 2003; 5: 350-6.
36. + plasma cells. Haematologica 2010; 95: 1016-20.
37. Jimenez-Boj E, Redlich K, Turk B, Hanslik-Schnabel B, Wanivenhaus A, Chott A, et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 2005; 175: 2579-88. (Pubitemid 41113871)
38. Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren's syndrome. Ann Rheum Dis 2007; 66: 23-7. (Pubitemid 46044856)
39. Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X,. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009; 11: R114.
40. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P,. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2993-9.
41. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-20.
42. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC,. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723-32.